Can Eli Lilly’s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Eli Lilly (NYSE:LLY | LLY Price Prediction) presents mid-stage data on eloraTZP, a combination of eloralintide and tirzepatide, at a European Association for the Study of Diabetes symposium on September 30.
An earlier Phase 1 study hinted the pairing could deepen weight loss beyond tirzepatide alone. The mid-stage trial enrolls a larger group of adults with obesity or overweight and type 2 diabetes.
The stock trades near $1,152.44 on obesity-franchise expectations that leave little room for disappointment.
What the Data Has to Show
Watch four metrics: weight loss magnitude, dose arms, tolerability, and discontinuation rates. The combination must separate from each individual component, not just placebo, or the strategic rationale weakens.
Discontinuations matter because tolerability drives persistence and persistence drives revenue. A combo that adds modest weight loss but pushes more patients off therapy is a hollow win.
Mounjaro and Zepbound delivered $14.87 billion in the second quarter, with Mounjaro up 91% year over year. That scale outpaces Novo Nordisk (NYSE:NVO), whose GLP-1 franchise faces headwinds.
Viking Therapeutics (NASDAQ:VKTX) poses a smaller but real threat with VK2735. A convincing eloraTZP result would raise the bar for both competitors.
Valuation Already Assumes a Win
Lilly trades at a forward earnings multiple of 24x against a trailing 38x, and a market capitalization near $1.01 trillion. Options markets show the caution: put/call ratios of 2.33 for the October 2 expiration and 4.67 for October 9.
U.S. realized prices already fell about 9% ex-rebates last quarter. A readout that merely matches Zepbound would leave the multiple exposed while pricing pressure continues.
Bull and Bear Case for LLY Stock
The bull case: eloraTZP shows meaningfully deeper weight loss than tirzepatide alone with clean tolerability, defending the franchise as retatrutide moves toward a Q1 2027 BLA submission. CEO David A. Ricks has raised guidance, with full-year revenue now guided to $85.0 billion to $87.0 billion.
The bear case: match-level efficacy, worse GI tolerability, or higher discontinuations make the combo redundant. A demanding multiple contracts against a $1 trillion base, with analyst targets averaging $1,324.87 offering modest cushion.
The deciding variable is the September 30 discontinuation curve and dose-response separation from tirzepatide monotherapy, because that number tells you whether eloraTZP is a franchise extension or an expensive line extension.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.
